Exencial Wealth Advisors LLC Sells 5,932 Shares of Novartis AG (NYSE:NVS)

Exencial Wealth Advisors LLC trimmed its holdings in shares of Novartis AG (NYSE:NVSFree Report) by 4.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 144,046 shares of the company’s stock after selling 5,932 shares during the quarter. Exencial Wealth Advisors LLC’s holdings in Novartis were worth $14,544,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Frazier Financial Advisors LLC purchased a new position in Novartis during the fourth quarter valued at approximately $26,000. Operose Advisors LLC purchased a new position in Novartis during the third quarter valued at approximately $28,000. Planned Solutions Inc. purchased a new position in Novartis during the fourth quarter valued at approximately $31,000. AdvisorNet Financial Inc lifted its holdings in Novartis by 480.0% during the fourth quarter. AdvisorNet Financial Inc now owns 348 shares of the company’s stock valued at $35,000 after purchasing an additional 288 shares in the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new position in Novartis during the third quarter valued at approximately $39,000. 13.12% of the stock is currently owned by institutional investors.

Novartis Price Performance

Novartis stock opened at $106.07 on Friday. The company has a market cap of $216.81 billion, a price-to-earnings ratio of 14.31, a PEG ratio of 1.62 and a beta of 0.58. The firm’s fifty day moving average is $98.67 and its 200 day moving average is $100.23. The company has a quick ratio of 0.71, a current ratio of 0.90 and a debt-to-equity ratio of 0.43. Novartis AG has a 52-week low of $92.19 and a 52-week high of $108.78.

Novartis (NYSE:NVSGet Free Report) last released its quarterly earnings results on Tuesday, April 23rd. The company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.73 by $0.07. Novartis had a net margin of 31.33% and a return on equity of 32.15%. The company had revenue of $11.83 billion for the quarter, compared to the consensus estimate of $11.50 billion. Sell-side analysts forecast that Novartis AG will post 7.27 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Novartis in a report on Thursday, May 30th. They issued a “buy” rating and a $120.00 target price on the stock. BMO Capital Markets boosted their target price on shares of Novartis from $114.00 to $116.00 and gave the stock a “market perform” rating in a report on Wednesday, April 24th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Novartis currently has an average rating of “Moderate Buy” and a consensus target price of $116.67.

View Our Latest Stock Analysis on Novartis

About Novartis

(Free Report)

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Read More

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVSFree Report).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.